EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+0.43%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.29B
AUM Growth
+$3.29B
(-3%)
Cap. Flow
+$18M
Cap. Flow
% of AUM
0.55%
Top 10 Holdings %
Top 10 Hldgs %
70.15%
Holding
84
New
9
Increased
10
Reduced
4
Closed
18
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$63.3M |
| 2 |
Zymeworks
ZYME
|
$59.5M |
| 3 |
Adicet Bio
ACET
|
$31.8M |
| 4 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$29.6M |
| 5 |
Dyne Therapeutics
DYN
|
$26.9M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$70.9M |
| 2 |
Gossamer Bio
GOSS
|
$49.8M |
| 3 |
Avidity Biosciences
RNA
|
$47.3M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$39.1M |
| 5 |
Design Therapeutics
DSGN
|
$16.8M |
Sector Composition
| 1 | Healthcare | 99.78% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $698M | 21.24% | 11,584,280 | – | – |
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $389M | 11.83% | 2,999,453 | – | – |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $268M | 8.16% | 5,183,431 | – | – |
|
4
AnaptysBio
ANAB
$569M
| $233M | 7.09% | 7,521,024 | – | – |
|
5
Galapagos
GLPG
$2.07B
| $166M | 5.04% | 3,730,730 +533,230 | +17% | +$23.7M |
|
6
Xencor
XNCR
$580M
| $138M | 4.19% | 5,282,516 | – | – |
|
7
Arvinas
ARVN
$568M
| $107M | 3.25% | 3,123,300 | – | – |
|
|
8
Revolution Medicines
RVMD
$7.1B
| $106M | 3.23% | 4,458,731 +2,656,884 | +147% | +$63.3M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $106M | 3.22% | 3,951,566 | – | – |
|
10
Acadia Pharmaceuticals
ACAD
$4.38B
| $95.4M | 2.9% | 5,991,479 | – | – |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $90M | 2.74% | 3,460,208 | – | – |
|
12
Kura Oncology
KURA
$686M
| $82.4M | 2.51% | 6,638,371 | – | – |
|
13
Zai Lab
ZLAB
$3.68B
| $66.2M | 2.02% | 2,157,686 +127,434 | +6% | +$3.91M |
|
14
Relay Therapeutics
RLAY
$619M
| $62.2M | 1.89% | 4,163,824 | – | – |
|
|
15
Zymeworks
ZYME
$1.12B
| $59.5M | 1.81% | +7,568,573 | New | +$59.5M |
|
16
Alector
ALEC
$238M
| $37.4M | 1.14% | 4,056,548 | – | – |
|
|
NGM
17
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $32.3M | 0.98% | 6,435,518 +5,894,410 | +1,089% | +$29.6M |
|
|
18
Adicet Bio
ACET
$59.9M
| $31.8M | 0.97% | +3,560,700 | New | +$31.8M |
|
19
Edgewise Therapeutics
EWTX
$1.51B
| $31.2M | 0.95% | 3,493,194 | – | – |
|
20
Tango Therapeutics
TNGX
$747M
| $30.5M | 0.93% | 4,201,414 | – | – |
|
21
Atea Pharmaceuticals
AVIR
$267M
| $29.7M | 0.91% | 6,184,861 | – | – |
|
22
Voyager Therapeutics
VYGR
$186M
| $29M | 0.88% | 4,753,907 | – | – |
|
23
Allogene Therapeutics
ALLO
$251M
| $28.2M | 0.86% | 4,488,200 | – | – |
|
|
24
Dyne Therapeutics
DYN
$1.92B
| $26.9M | 0.82% | +2,322,384 | New | +$26.9M |
|
25
Nuvation Bio
NUVB
$1.02B
| $26.7M | 0.81% | 13,896,543 | – | – |
|